Discontinuing alendronate after 5 years of treatment, does it affect fracture risk ?
Effects of Continuing or Stopping Alendronate After 5 Years of Treatment The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial
JAMA. 2006 Dec 27;296(24):2927-38.1099 postmenopausal women randomized to receive alendronate in FIT and underwent 5 years of prior alendronate treatment were further randomized to receive 5 mg or 10 mg of alendronate, or a placebo for 5 years. The results of the study revealed that women who had discontinued alendronate treatment after 5 years experienced a moderate decline in bone mineral density and a moderate rise in biochemical markers, but did not experience a rise in fracture risk other than for clinical vertebral fractures.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
